Latanoprost
Based on 5 publication(s) in Google Scholar
Latanoprost (PHXA41) is a prostaglandin F2α analogue and can be used for glaucoma research. Latanoprost can effectively pass through cornea and be hydrolyzed by esterase to latanoprost acid. latanoprost acid is an F-prostaglandin (FP) receptor agonist, and can effectively reduce intraocular pressure (IOP) by increasing the outflow of aqueous humor through uvea.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.85%
- CAS. Nr.: 130209-82-4
- Formel: C26H40O5
- Molecular Weight:432.59
-
Speicherung:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Lipid Compound Library
HY-L043
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Angiogenesis-Related Compound Library
HY-L088
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Latanoprost
More
Biologische Aktivität
|
FP Receptor |
Benzalkonium chloride latanoprost (BAK-latanoprost) and 0.02% BAK induce significant apoptosis in the apical layers that correlated with the significant decrease of cell viability. Preservative-free latanoprost (PF-latanoprost) slightly decreases cell viability and few apoptotic cells are found in the superficial layers, without reaching statistical significance compared with PBS[1]. Latanoprost (0.1 μM) significantly increases cell viability as compared with control. Meanwhile, 0.1 μM latanoprost results in the obvious promotion of neurite outgrowth similar to ciliary neurotrophic factor (CNTF) and simultaneously increases the levels of p-Akt and p-mTOR expression. Latanoprost can promote neurite outgrowth through an FP receptor-mediated modulation of the PI3K-Akt-mTOR signaling pathway[3]. Latanoprost (0.03 or 0.3 μg/mL) and bimatoprost increase MMP-9 activity by 75% ± 27% and 75% ± 24%, respectively, in human CBSM cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 130209-82-4
-
Appearance Liquid (Density: 1.093±0.06 g/cm3)
-
Molecular Weight 432.59
-
Formel C26H40O5
-
Color Colorless to light yellow
-
SMILES
O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCC2=CC=CC=C2)[C@H](O)C[C@@H]1O
-
Synonyms
PHXA41
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
-
Phytomedicine
WenDan Decoction activates neuronal autophagy in the hippocampus via the gut-brain axis to improve depressive-like behavior in HFD mice. [Abstract]2025 Dec 8:150:157686. PMID: 41391369 -
Ocul Surf
New trends towards glaucoma treatment: Topical osmoprotective microemulsions loaded with latanoprost. [Abstract]2023 Jul:29:314-330. PMID: 37295473 -
Drug Deliv Transl Res
Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents. [Abstract]2024 Oct;14(10):2804-2822. PMID: 38602615 -
Lösungsmittel & Löslichkeit
H2O : 100 mg/mL (231.17 mM; Need ultrasonic)
Ethanol : 100 mg/mL (231.17 mM; Need ultrasonic)
DMSO : ≥ 100 mg/mL (231.17 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.81 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.81 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (231.17 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protokoll
Cellular viability is evaluated in duplicate at 24 hours with the MTT assay. The 3D-HCEs are transferred to 24-well plates containing 300 μL of MTT solution diluted at 0.5 mg/mL in the culture medium, and 300 μL of the same MTT solution is applied on the apical surface of the 3D-HCEs. Reconstituted tissues are incubated for 3 hours at 37°C. Then they are transferred to 24-well plates containing 750-μL isopropanol, and 750-μL isopropanol is added to the apical surface of the 3D-HCEs. The plates are agitated for 2 hours at room temperature before reading the optical density (OD) at 570 nm versus OD 690 nm. The results are expressed as percentages of cell viability (mean ± SD) compared with the negative control (PBS).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (282 KB)
-
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Pauly A, et al. In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation. Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8172-80. [Content Brief]
[2]. Zheng J, et al. Latanoprost promotes neurite outgrowth in differentiated RGC-5 cells via the PI3K-Akt-mTOR signaling pathway. Cell Mol Neurobiol. 2011 May;31(4):597-604. [Content Brief]
[3]. Tsai S, et al. The effect of topical latanoprost on anterior segment anatomic relationships in normal dogs. Vet Ophthalmol. 2013 Sep;16(5):370-6. [Content Brief]
[4]. Ooi YH, et al. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5259-65. [Content Brief]
[5]. B'Ann True Gabelt, et al. Prostaglandin Subtype-Selective and Non-Selective IOP-Lowering Comparison in Monkeys. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / Ethanol / DMSO | 1 mM | 2.3117 mL | 11.5583 mL | 23.1166 mL | 57.7914 mL |
| 5 mM | 0.4623 mL | 2.3117 mL | 4.6233 mL | 11.5583 mL | |
| 10 mM | 0.2312 mL | 1.1558 mL | 2.3117 mL | 5.7791 mL | |
| 15 mM | 0.1541 mL | 0.7706 mL | 1.5411 mL | 3.8528 mL | |
| 20 mM | 0.1156 mL | 0.5779 mL | 1.1558 mL | 2.8896 mL | |
| 25 mM | 0.0925 mL | 0.4623 mL | 0.9247 mL | 2.3117 mL | |
| 30 mM | 0.0771 mL | 0.3853 mL | 0.7706 mL | 1.9264 mL | |
| 40 mM | 0.0578 mL | 0.2890 mL | 0.5779 mL | 1.4448 mL | |
| 50 mM | 0.0462 mL | 0.2312 mL | 0.4623 mL | 1.1558 mL | |
| 60 mM | 0.0385 mL | 0.1926 mL | 0.3853 mL | 0.9632 mL | |
| 80 mM | 0.0289 mL | 0.1445 mL | 0.2890 mL | 0.7224 mL | |
| 100 mM | 0.0231 mL | 0.1156 mL | 0.2312 mL | 0.5779 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Latanoprost Related Classifications
HY-B0577 Related Classifications
Powered by Bioz